Navigation Links
TREVENTIS Corporation Closes $4.4 Million Financing with Wellcome Trust
Date:9/19/2013

PHILADELPHIA, Sept. 19, 2013 /PRNewswire/ -- TREVENTIS Corporation announced today that it received a $4.4 million Seeding Drug Discovery Award from the Wellcome Trust to continue development of a potentially disease-modifying drug for the treatment of Alzheimer's disease (AD). 

Recent studies demonstrate that the misfolding and subsequent aggregation of both beta-amyloid and tau are primary events in the Alzheimer's disease process.  Using a novel, proprietary drug design platform, TREVENTIS synthesized a class of organic drug-like molecules with the unique capability of binding to both beta-amyloid and tau, preventing aggregation of both proteins using a single drug. 

This financing supports the continued progression of TREVENTIS' compounds with the initial objective of delivering an AD drug candidate into first-in-man clinical testing.  The ultimate goal is to provide a drug that effectively and safely prevents the progression of AD.

"This financing signals a transformational event for TREVENTIS.  It provides the resources necessary to progress our critically important drug development and validates the scientific approach we have taken" said William McIntosh, Chairman and CEO, TREVENTIS. 

The principal investigator, board-certified neurologist and renowned medicinal chemist, Donald F. Weaver, MD, PhD, said: "I am deeply honored to receive this funding from the Wellcome Trust.  It enables us to advance important research that will profoundly and positively impact our efforts to treat people with chronic neurological dementias such as Alzheimer's."

About TREVENTIS Corporation 
TREVENTIS is headquartered in Southeastern Pennsylvania and has research operations in Toronto, Ontario, and Halifax, Nova Scotia, Canada.  The company is focused on the discovery and early stage development of disease-modifying small molecule drugs for Alzheimer's and other protein misfolding diseases.  In addition to its therapeutic programs, TREVENTIS has a novel approach to the development of diagnostics for early diagnosis and monitoring of treatment effects in Alzheimer's disease.  www.TREVENTIS.com

About Wellcome Trust
The Wellcome Trust is a global charitable foundation dedicated to achieving extraordinary improvements in human and animal health.  It supports the brightest minds in biomedical research and the medical humanities.  The Trust's breadth of support includes public engagement, education and the application of research to improve health.  It is independent of both political and commercial interests.  www.wellcome.ac.uk  U.S. Contact:  L. William McIntoshCanada Contact:  Dr. Mark ReedChairman and CEO, TREVENTISVP, Therapeutics, TREVENTISPhone: 610-488-608Phone: 647-924-9736wmcintosh@treventis.com  

mreed@treventis.com  


'/>"/>
SOURCE TREVENTIS Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. B. Riley Exclusive Financial Advisor to Mirth Corporation in Connection with its Corporate Sale to Quality Systems, Inc.
2. Gentris Corporation Launches Next Generation Human Transcriptome Array
3. Euclid Systems Corporation signs agreement with Wenzhou Medical University to promote the use of Orthokeratology to control myopia progression
4. Unilife Corporation Announces Financial Results For Fiscal Year 2013 Fourth Quarter
5. Celsion Corporation Announces Combined Clinical Data from Two Phase I Trials to be Presented at the 2013 San Antonio Breast Cancer Conference
6. The X-Change Corporation To Announce Corporate Name Change Next Week; New Industry-Driven Branding to Commence For Global Activities, Services, Product Lines, and Website
7. Unilife Corporation To Announce Financial Results For Fiscal Year 2013 Fourth Quarter And Year End On Tuesday, September 10, 2013
8. Arrayit Corporation Holds Successful Meeting with DHK Medical Products CEO
9. MGC Diagnostics Corporation Reports 2013 Third Quarter Operating Results
10. Immune Pharmaceuticals Completes Merger with EpiCept Corporation
11. Luminex Corporation To Present At Morgan Stanley Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... , Oct. 2, 2017 Halo Labs announces the ... analysis system called the HORIZON at MIBio 2017 in ... subvisible and visible particulate matter in biopharmaceutical samples with unprecedented speed ... of the novel technique Backgrounded Membrane Imaging. ... The HORIZON subvisible particle analysis system ...
(Date:9/27/2017)... and NEW YORK , Sept. 27, 2017  DarioHealth ... and big data solutions, today announced that its MyDario product is expected ... local TV listings for when The Dr. Oz Show airs in your ... The nine-time Emmy ... ...
(Date:9/22/2017)... , Sept. 22, 2017 AVACEN Medical (AVACEN) ... is now successfully helping those with the widespread pain ... Fibromyalgia diagnosed Amanda in Essex, England ... washing my hair, experiencing no sleep at all, tremendous ... spasm… I cannot recommend [the AVACEN 100] enough, how ...
Breaking Medicine Technology:
(Date:10/13/2017)... Vegas, Nevada (PRWEB) , ... October 13, 2017 , ... ... 7® Hemp CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD ... dose required and providing a CBD form that can be easily incorporated into liquid ...
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) ... a collection of specialty vendors and unique items from across the nation, this holiday-themed ... and wellness services offered by the VNA. The boutique will be open Saturday, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in agile ... a contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise ... use of Agile methodologies in a consistent and high value manner across CMS ...
(Date:10/12/2017)... ... 12, 2017 , ... Planet Fitness, one of the largest and fastest growing ... open a flagship location in Covington, LA at 401 N. U.S. Highway 190, in ... to Office Depot in the Holiday Square shopping center. Its location allows it to ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information ... we intend to develop to enable prevention of a major side effect of ... loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label ...
Breaking Medicine News(10 mins):